Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs)

Pearl, Michael L.; Dong, H.; Tulley, Shaun; Zhao, Qiang; Golightly, Marc G.; Zucker, Stanley; Chen, Wen-Tien

doi:10.1016/j.ygyno.2015.03.002

Cited by 60 publications

(71 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same group also investigated the predictive value of CTC levels in a small group of 31 ovarian cancer patients that received standard taxol/carboplatin chemotherapy, where blood specimens were obtained at different time points, before and after surgery and up to 24 months after chemotherapy treatment. Using the same assay [27], they showed a statistically significant association between CTC levels and disease progression [26].…”

Section: Circulating Tumor Cells (Ctcs)mentioning

confidence: 95%

Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA

Giannopoulou

Kasimir‐Bauer

Lianidou

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Ovarian cancer remains the most lethal disease among gynecological malignancies despite the plethora of research studies during the last decades. The majority of patients are diagnosed in an advanced stage and exhibit resistance to standard chemotherapy. Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) represent the main liquid biopsy approaches that offer a minimally invasive sample collection. Both have shown a diagnostic, prognostic and predictive value in many types of solid malignancies and recent studies attempted to shed light on their role in ovarian cancer. This review is mainly focused on the clinical value of both CTCs and ctDNA in ovarian cancer and, more specifically, on their potential as diagnostic, prognostic and predictive tumor biomarkers.

show abstract

Section: Circulating Tumor Cells (Ctcs)mentioning

confidence: 95%

Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA

Giannopoulou

Kasimir‐Bauer

Lianidou

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…Blood collection and transport were previously described. 14 Briefly, 2-20 mL of blood was collected from patients using Vacutainer® tubes (Becton Dickinson; green top, sodium heparin as anticoagulant) and processed within 48 hours from collection. Blood was kept at 2-8°C when storage longer than 4 hours was needed.…”

Section: Patients Blood Ascites and Tissue Collection And Tumor mentioning

confidence: 99%

“…To address the low number and heterogeneity of CTCs under investigation, here we used the functional collagen‐based adhesion matrix (CAM) enrichment method capable of enriching both viable bulk tumor cells and TP cells in various cellular sources from patients with high sensitivity to develop a novel patient‐derived CTC model for predicting metastatic progression and treatment response. We identified TP cells by their invasive phenotype including expression of functional CAM uptake and markers for epithelial stem cells such as CD44 and invasiveness (seprase), the method identical to that identifying iCTCs in blood of patients with both metastatic and early stage cancers of the breast, ovary, gastrointestines, lung, pancreas, and prostate . We demonstrated potential roles of patient‐derived iCTCs in metastatic progression and therapeutic response in experimental mice using appearance of mouse iCTCs and micrometastases in the lung or liver as well as after inoculating experimental mice with cells with altered gene expression via RNAi, peptides, and monoclonal antibodies respectively, against seprase.…”

Section: Introductionmentioning

confidence: 99%

“…We identified TP cells by their invasive phenotype including expression of functional CAM uptake and markers for epithelial stem cells such as CD44 and invasiveness (seprase), the method identical to that identifying iCTCs in blood of patients with both metastatic and early stage cancers of the breast, ovary, gastrointestines, lung, pancreas, and prostate. 1,[11][12][13][14][15][16][17][18][19] We demonstrated potential roles of patient-derived iCTCs in metastatic progression and therapeutic response in experimental mice using appearance of mouse iCTCs and micrometastases in the lung or liver as well as after inoculating experimental mice with cells with altered gene expression via RNAi, peptides, and monoclonal antibodies respectively, against seprase.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The propensity of invasive circulating tumor cells (iCTCs) in metastatic progression and therapeutic responsiveness

et al. 2019

Self Cite

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) are important clinical indicators of metastatic progression and treatment efficacy. However, because of their low number and heterogeneity, reliable patient‐derived CTC models are not readily available. We report here the isolation and characterization of the invasive population of CTCs, iCTCs, from blood of 10 patients with epithelial ovarian cancer (EOC) and one pancreatic cancer patient based on the avidity of tumor cells toward an artificial collagen‐based adhesion matrix (CAM), in comparison with tumor progenitor (TP) cells isolated from tumor cell lines, tumors and ascites from EOC patients. CAM‐avid cells identified to be iCTCs were indistinguishable with TP cells using either functional CAM uptake or surface markers (seprase and CD44). In addition, iCTCs were characterized using peritoneal and spontaneous metastasis models in vivo to evaluate their metastatic propensity and therapeutic response. TP cells and iCTCs had a doubling time of about 34‐42 hours. TP cells were rare (<3.5%) in most patient‐derived specimens, however, iCTCs emigrated into blood, at a high frequency, 64.2% (n = 49). Approximately 500 patient‐derived iCTCs recapitulated formation of iCTCs in mouse blood and formed micrometastases in the liver and/or lung, a degree of metastatic spread equivalent to the inoculation of 5 × 10 5 bulk tumor cells isolated from ascites and tumors. iCTCs were shown to be novel therapeutic targets for blocking metastasis using the reduced formation of iCTCs and micrometastases by RNAi, peptides, and monoclonal antibodies against seprase.

show abstract

“…The first assay was described approximately 10 years ago and is based on the ability of tumor cells to invade a collagen matrix in vitro. This assay has been used for enumeration and molecular characterization of CTCs in ovarian and prostate cancer (16,17 ), but to our knowledge, its efficiency to culture CTCs remains to be demonstrated.…”

Section: Enrichment Of Live Ctcsmentioning

confidence: 99%

Functional Studies on Viable Circulating Tumor Cells

Pantel

Alix‐Panabières

2016

Clinical Chemistry

View full text Add to dashboard Cite

BACKGROUND Research on circulating tumor cells (CTCs) as new biomarkers has received great attention over the past decade. In particular, the capture and analysis of CTCs as “liquid biopsies” provides the possibility to avoid invasive tissue biopsies, with obvious implications in cancer diagnostics. CONTENT The focus of this review is to describe and discuss how functional studies on viable CTCs can enlarge the spectrum of applications of liquid biopsies, with emphasis on breast, prostate, colon, and lung cancer as the major tumor entities in industrialized countries. The low number of CTCs in the peripheral blood of most cancer patients makes challenging the in vitro culture of CTCs. Epithelial tumor cells are difficult to culture, even when starting with millions of tumor cells. Recently, several groups have achieved important advances in the in vitro and in vivo expansion of CTCs from cancer patients at very advanced stages with higher amounts of CTCs. Here, we present current technologies to enrich and detect viable human CTCs, including positive and negative enrichment strategies that are based on antigen expression and physical properties of CTCs. We also discuss published data about functional studies on CTCs that use in vitro and in vivo models. SUMMARY Functional analyses on CTCs offer the possibility to identify the biological properties of metastatic cells, including the identification of metastasis-initiating cells. Moreover, CTC-derived cell lines and xenografts might reveal new therapeutic targets and can be used for drug screening.

show abstract

Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs)

Cited by 60 publications

References 39 publications

Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA

Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA

The propensity of invasive circulating tumor cells (iCTCs) in metastatic progression and therapeutic responsiveness

Functional Studies on Viable Circulating Tumor Cells

Contact Info

Product

Resources

About